<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107354</url>
  </required_header>
  <id_info>
    <org_study_id>1334.00</org_study_id>
    <secondary_id>CDR0000407784</secondary_id>
    <nct_id>NCT00107354</nct_id>
  </id_info>
  <brief_title>Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant</brief_title>
  <official_title>Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the&#xD;
      immune system in different ways and stop cancer cells from growing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of cellular adoptive immunotherapy&#xD;
      in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, or&#xD;
      myelodysplastic syndromes that relapsed after donor stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxic effects of adoptive immunotherapy comprising CD8-positive minor&#xD;
           histocompatability antigen-specific cytotoxic T-lymphocytes in patients with acute&#xD;
           myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes that&#xD;
           relapsed after allogeneic hematopoietic stem cell transplantation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the persistence of adoptively transfused T cells in vivo and assess their&#xD;
           migration to the bone marrow in these patients.&#xD;
&#xD;
        -  Determine the anti-leukemic activity of this therapy in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, open-label, nonrandomized study.&#xD;
&#xD;
        -  Leukapheresis: Patients undergo leukapheresis to obtain peripheral blood mononuclear&#xD;
           cells (PBMCs) before transplantation. Donors undergo leukapheresis to obtain PBMCs to&#xD;
           use as feeder cells for generating adoptive immunotherapy. Patient PBMCs are combined&#xD;
           with donor PBMCs and expanded in vitro to generate CD8-positive minor histocompatability&#xD;
           antigen-specific cytotoxic T-lymphocytes (CTLs) for adoptive immunotherapy.&#xD;
&#xD;
        -  Transplantation: Patients undergo allogeneic bone marrow or peripheral blood stem cell&#xD;
           transplantation. Patients with a morphologic or flow cytometric relapse on or after day&#xD;
           100 post-transplantation proceed to cytoreductive chemotherapy. Patients with a&#xD;
           molecular or cytogenetic relapse on or after day 100 post-transplantation proceed&#xD;
           directly to adoptive immunotherapy. Patients with relapsed disease before day 100&#xD;
           post-transplantation are eligible to receive adoptive immunotherapy at a later date&#xD;
           provided the patient continues to relapse and CTLs are available.&#xD;
&#xD;
        -  Cytoreductive chemotherapy: The chemotherapy regimen for each patient is determined&#xD;
           after consideration of prior chemotherapy, type of leukemia, and other clinical&#xD;
           parameters. Two regimens to consider are:&#xD;
&#xD;
             -  Mitoxantrone IV and etoposide IV on days -6 to -2&#xD;
&#xD;
             -  High-dose cytarabine IV over 2 hours twice daily on days -6, -4, and -2 Patients&#xD;
                achieving a complete remission after completion of cytoreductive chemotherapy&#xD;
                proceed to adoptive immunotherapy.&#xD;
&#xD;
        -  Adoptive immunotherapy: Within 2-3 days after completion of cytoreductive chemotherapy,&#xD;
           patients receive CTLs IV over 1-2 hours on days 0, 4, 11, 21, and 28 in the absence of&#xD;
           unacceptable toxicity. Patients with evidence of persistent disease on or after day 35&#xD;
           OR relapsed disease after an initial response to CTLs receive a sixth infusion of CTLs&#xD;
           followed, no more than 24 hours later, by interleukin-2 subcutaneously once daily for up&#xD;
           14 total doses in the absence of unacceptable toxicity. Patients with subsequent&#xD;
           relapsed disease after day 48 may be eligible for retreatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed with bone marrow aspiration every&#xD;
      3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-30 patients (10-15 with acute myeloid leukemia or&#xD;
      myelodysplastic syndromes AND 10-15 with acute lymphoblastic leukemia) will be accrued for&#xD;
      this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vivo persistence of adoptively transferred T cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration of adoptively transferred T cells to the bone marrow</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antileukemic activity</measure>
  </secondary_outcome>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Undergoing allogeneic hematopoietic stem cell transplantation* from a major&#xD;
             histocompatability complex (MHC)-identical related donor for 1 of the following:&#xD;
&#xD;
               -  Primary refractory acute myelogenous leukemia (AML) or acute lymphoblastic&#xD;
                  leukemia (ALL)&#xD;
&#xD;
               -  AML or ALL beyond first remission&#xD;
&#xD;
               -  Therapy-related AML at any stage&#xD;
&#xD;
               -  Philadelphia chromosome (bcr-abl)-positive p190-positive ALL at any stage&#xD;
&#xD;
               -  Acute leukemia at any stage arising from myelodysplastic syndromes or&#xD;
                  myeloproliferative disorders, including any of the following:&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  Chronic myelogenous leukemia&#xD;
&#xD;
                    -  Polycythemia vera&#xD;
&#xD;
                    -  Essential thrombocytosis&#xD;
&#xD;
                    -  Agnogenic myeloid metaplasia with myelofibrosis&#xD;
&#xD;
               -  Refractory anemia with excess blasts&#xD;
&#xD;
               -  Refractory anemia with excess blasts in transformation NOTE: *Patients must be&#xD;
                  enrolled on study prior to undergoing transplantation&#xD;
&#xD;
          -  Relapsed disease post-transplantation, as evidenced by 1 of the following criteria:&#xD;
&#xD;
               -  Morphologic relapse, as defined by 1 or more of the following:&#xD;
&#xD;
                    -  Peripheral blasts in the absence of growth factor therapy&#xD;
&#xD;
                    -  Bone marrow blasts &gt; 5% of nucleated cells&#xD;
&#xD;
                    -  Extramedullary chloroma or granulocytic sarcoma&#xD;
&#xD;
               -  Flow cytometric relapse, as defined by the appearance of cells with abnormal&#xD;
                  immunophenotype consistent with leukemia relapse in the peripheral blood or bone&#xD;
                  marrow (detected before transplantation)&#xD;
&#xD;
               -  Cytogenetic relapse, as defined by the appearance in 1 or more metaphases from&#xD;
                  bone marrow or peripheral blood cells of either a non-constitutional cytogenetic&#xD;
                  abnormality detected in at least 1 cytogenetic study performed before&#xD;
                  transplantation OR a new abnormality known to be associated with leukemia&#xD;
&#xD;
               -  Molecular relapse, as defined by 1 of the following:&#xD;
&#xD;
                    -  1 or more positive polymerase chain reaction (PCR) assays for clonotypic&#xD;
                       immunoglobulin heavy chain or T-cell receptor gene rearrangement in patients&#xD;
                       transplanted for B- or T-cell ALL respectively&#xD;
&#xD;
                    -  1 or more positive post-transplantation reverse transcription PCR assays for&#xD;
                       p190 BCR-ABL mRNA fusion transcripts in patients transplanted for&#xD;
                       Philadelphia chromosome-positive p190-positive ALL&#xD;
&#xD;
          -  No grade III or IV acute graft-versus-host disease (GVHD)**&#xD;
&#xD;
          -  No extensive chronic GVHD** NOTE: **At time of post-transplant relapse&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  14 and over (patients &lt; 14 years of age may be eligible if they are deemed to be of&#xD;
             sufficient height and weight by the pediatric attending physician)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100% (at time of post-transplant relapse)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No preexisting major nonhematopoietic organ toxicity â‰¥ grade 3 (at time of&#xD;
             post-transplant relapse)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent immunosuppressive steroid therapy for GVHD allowed provided both of the&#xD;
             following are true:&#xD;
&#xD;
               -  Able to taper steroid dose to &lt; 0.5 mg/kg/day&#xD;
&#xD;
               -  No increase of &gt; 1 grade in acute GVHD OR progression of chronic GVHD within 14&#xD;
                  days after dose change&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edus H. Warren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2010</last_update_posted>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>T-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>B-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

